--- title: "Allarity Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/295977932.md" datetime: "2026-08-14T21:13:42.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295977932.md) - [en](https://longbridge.com/en/news/295977932.md) - [zh-HK](https://longbridge.com/zh-HK/news/295977932.md) --- # Allarity Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0 Revenue: As of FY2026 Q2, the actual value is USD 0. EPS: As of FY2026 Q2, the actual value is USD -0.21, beating the estimate of USD -0.25. EBIT: As of FY2026 Q2, the actual value is USD -3.607 M. #### Cash Position As of June 30, 2026, Allarity Therapeutics, Inc. reported cash and restricted cash totaling $26.9 million, an increase from $14.7 million as of June 30, 2025. Cash was $16,982 thousand as of June 30, 2026, compared to $14,687 thousand as of December 31, 2025. Restricted cash was $9,999 thousand as of June 30, 2026, compared to $0 as of December 31, 2025. The company used $2.6 million of cash in operating activities during the second quarter of 2026. #### Revenue Allarity Therapeutics, Inc. reported no license revenue for the three months ended June 30, 2026, or June 30, 2025. For the six months ended June 30, 2026, license revenue was $25 thousand, compared to $0 for the six months ended June 30, 2025. #### Research and Development (R&D) Expenses R&D expenses for the second quarter of 2026 were $1,345 thousand, a decrease from $2,321 thousand for the second quarter of 2025. For the six months ended June 30, 2026, R&D expenses were $2,642 thousand, down from $3,724 thousand for the same period in 2025. #### General and Administrative (G&A) Expenses G&A expenses were $1,326 thousand for the second quarter of 2026, compared to $1,812 thousand for the second quarter of 2025. For the six months ended June 30, 2026, G&A expenses totaled $2,742 thousand, a reduction from $3,445 thousand for the six months ended June 30, 2025. #### Loss from Operations Loss from operations for the second quarter of 2026 was - $2,671 thousand, an improvement from - $4,133 thousand for the second quarter of 2025. For the six months ended June 30, 2026, the loss from operations was - $5,359 thousand, compared to - $7,169 thousand for the same period in 2025. #### Other Income (Expense), Net Total other income (expense), net, was - $734 thousand for the second quarter of 2026, a decrease from $1,813 thousand for the second quarter of 2025. For the six months ended June 30, 2026, total other income (expense), net, was - $796 thousand, compared to $2,117 thousand for the same period in 2025. This included interest income of $217 thousand in Q2 2026 versus $237 thousand in Q2 2025, interest expense of - $719 thousand in Q2 2026 versus - $12 thousand in Q2 2025, foreign exchange gains (losses) of - $104 thousand in Q2 2026 versus $1,588 thousand in Q2 2025, and a change in fair value of derivative and warrant liabilities of - $128 thousand in Q2 2026 versus $0 in Q2 2025. #### Net Loss Net loss for the second quarter of 2026 was - $3,405 thousand, compared to - $2,320 thousand for the second quarter of 2025. For the six months ended June 30, 2026, the net loss was - $6,155 thousand, an increase from - $5,052 thousand for the same period in 2025. #### Total Comprehensive Loss Total comprehensive loss for the second quarter of 2026 was - $3,672 thousand, an improvement from - $4,150 thousand for the second quarter of 2025. For the six months ended June 30, 2026, total comprehensive loss was - $6,480 thousand, compared to - $7,158 thousand for the same period in 2025. #### Operational Highlights Allarity Therapeutics, Inc. completed its Phase 3-ready manufacturing campaign for stenoparib, securing drug supply for late-stage clinical development. A key U.S. patent covering the stenoparib-specific DRP® companion diagnostic was granted, providing exclusivity into April 2042. The company also obtained CLIA certification for its in-house laboratory, enabling full control of DRP® testing to support U.S. clinical trials, and data presented at AACR 2026 linked higher stenoparib DRP® scores with enhanced overall survival in advanced ovarian cancer patients. #### Outlook / Guidance Allarity Therapeutics, Inc. aims to drive stenoparib forward as rapidly as possible, strengthening the foundation for accelerating its path toward FDA approval. The completed manufacturing campaign and CLIA certification are expected to reduce reliance on external laboratories, shorten turnaround times, and reduce costs, positioning the company for pivotal trials and potential commercialization. The company will continue enrolling patients in its Phase 2 clinical trials for advanced ovarian cancer and relapsed small cell lung cancer. ### Related Stocks - [ALLR.US](https://longbridge.com/en/quote/ALLR.US.md) ## Related News & Research - [Allarity Therapeutics secures CLIA certification for in-house DRP testing lab](https://longbridge.com/en/news/291945556.md) - [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md) - [Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)](https://longbridge.com/en/news/296112335.md) - [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md) - [Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September](https://longbridge.com/en/news/295792100.md)